Español
PDFs by language
Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
After being diagnosed with endometrial cancer, doctors will try to figure out if it has spread and, if so, how far. This process is called staging. The stage of a cancer describes how much and where cancer is in the body. Knowing how advanced the cancer is helps determine how best to treat it. The stage is one of the most important factors in deciding how to treat the cancer and determining how successful the treatment might be.
Doctors use diagnostic tests to determine the cancer's stage. They will need information based on samples of tissue collected during surgery. Because of this, staging may not be complete until all of the tests are finished and the surgery to remove the tumor has been done.
Endometrial cancer stages range from stage I (1) through IV (4). As a rule, the lower the number, the less the cancer has spread. A higher number, such as stage IV, means cancer has spread to other parts of the body. And within a stage, an earlier letter means a lower stage. Although each person’s cancer is unique, cancers with similar stages tend to have a similar outlook and are often treated in much the same way.
The 2 systems used for staging endometrial cancer are the FIGO (International Federation of Gynecology and Obstetrics) system and the American Joint Committee on Cancer TNM staging system.
They both stage (classify) this cancer based on 3 factors:
Numbers or letters after T, N, and M give more details about each of these factors. Higher numbers mean the cancer is more advanced. Once a person’s T, N, and M categories have been determined, this information is combined in a process called stage grouping to assign an overall stage.
The staging system in the table below uses the pathologic stage. It's determined by examining tissue removed during an operation. This is also known as surgical staging. Sometimes, if surgery isn't possible right away, the cancer will be given a clinical stage instead. The clinical stage is based on the results of a physical exam, biopsy, and imaging tests done before surgery. For more details, see Cancer Staging.
The FIGO staging system was updated in 2023 to reflect that some types of endometrial cancer are more aggressive than others.
Endometrial cancer staging can be complex, so ask your doctor to explain it to you in a way you understand.
.
Stage |
Stage grouping |
FIGO Stage |
Stage description* |
I |
T1 N0 M0 |
I |
The tumor is growing inside the uterus and/or is limited to the uterus and ovary for non-aggressive types. The cancer has not spread to nearby lymph nodes (N0) or to distant parts of the body (M0). |
IA |
T1a N0 M0 |
IA |
The tumor is limited to the endometrium (inner lining of the uterus) [IA1]. Or The tumor is a non-aggressive histologic type with growth less than halfway through the underlying muscle layer of the uterus (the myometrium) with no or focal lymphovascular space involvement (LVSI)** [IA2]. Or The tumor is a non-aggressive histologic type limited to the uterus and ovary [IA3]. The cancer has not spread to nearby lymph nodes (N0) or to distant parts of the body (M0). |
IB |
T1b N0 M0
|
IB |
Non-aggressive histologic types with growth more than halfway through the myometrium, but not beyond the body of the uterus with no or focal LVSI [IB] . The cancer has not spread to nearby lymph nodes (N0) or to distant parts of the body (M0). |
IC |
IC |
Aggressive histologic types limited to the endometrium. |
|
II
|
T2 N0 M0 |
II |
The cancer has spread from the body of the uterus and is growing into the supporting connective tissue of the cervix (called the cervical stroma). Or There is substantial LVSI. Or The cancer is an aggressive histologic type with any invasion into the myometrium. The cancer has not spread to nearby lymph nodes (N0) or to distant parts of the body (M0). |
IIA
|
IIA |
Non-aggressive histologic type with invasion of the cervical stroma
|
|
IIB
|
IIB |
Non-aggressive histologic type with substantial LVSI
|
|
IIC
|
T2 N0 M0 |
IIC |
Aggressive histologic type with any myometrial invasion |
III |
T3 N0 M0 |
III |
The cancer has spread outside the uterus, but has not spread to the inner lining of the rectum or urinary bladder (T3). |
IIIA |
T3a N0 M0 |
IIIA |
The tumor has spread to the ovary or fallopian tube (and criteria for stage IA3 is not met) [IIIA1]
The tumor has spread to the outer surface of the uterus (called the serosa) [IIIA2]. The cancer has not spread to nearby lymph nodes (N0) or to distant parts of the body (M0).
|
IIIB |
T3b N0 M0 |
IIIB |
The cancer has spread to the vagina or to the tissues around the uterus (the parametrium). [IIIB1] The cancer has spread to the pelvic peritoneum (The peritoneum is a sheet of smooth tissue that lines the abdomen and pelvis).[IIIB2] It has not spread to nearby lymph nodes (N0) or to distant parts of the body (M0). |
IIIC1 |
T1-T3 N1, N1mi or N1a M0 |
IIIC1 |
The cancer has spread to pelvic lymph nodes (N1, N1mi, or N1a), but not to lymph nodes around the aorta or distant parts of the body (M0). IIIC1i Micrometastasis+
|
IIIC2 |
T1-T3 N2, N2mi or N2a M0 |
IIIC2 |
The cancer has spread to lymph nodes around the aorta (para-aortic lymph nodes) (N2, N2mi, or N2a), but not to distant parts of the body (M0). IIIC2i The cancer has spread but is very small. It is a micrometastasis. IIIC2ii The cancer has spread but is very small. It is a macrometastasis. |
IVA |
T4 Any N M0 |
|
The cancer has spread to the inner lining of the rectum or urinary bladder (called the mucosa) (T4). It may or may not have spread to nearby lymph nodes (Any N), but has not spread to distant parts of the body (M0). |
IVB |
Any T Any N M1 |
IVB |
The cancer has spread to the abdominal peritoneum. The cancer can be any size (Any T) and it might or might not have spread to other lymph nodes (Any N). |
IVC | IVC | The cancer has spread to distant parts of the body such as lungs, liver, brain or bone or has spread to lymph nodes outside of the abdomen or lymph nodes above the kidneys. |
*The following additional categories are not listed on the table above:
A pathology report may also indicate isolated tumor cells (ITCs). This is noted when small amounts of tumor (<0.2mm and <200 cells) are found in the lymph nodes. The significance of this finding is unknown at this time, but it will be noted as pN0(i+).
**Lymphovascular space involvement (LVSI) = tumor cells are found around or near blood vessels or the lymph system.
+Micrometastasis = 0.2-2mm and/or >200 cells.
^Macrometastasis = larger than 2 mm.
Doctors can also describe this type of cancer by its grade (G). The grade describes how closely cancer cells look like healthy cells when seen with a microscope.
The doctor compares the cancerous tissue with healthy tissue. Healthy tissue usually has many different types of cells grouped together.
The cancer’s grade may help the doctor predict how quickly the cancer will grow. In general, the slower the growth, the better the prognosis.
The letter "G" is used to define a grade for uterine cancer.
GX: The grade cannot be evaluated.
G1: The cells are well differentiated.
G2: The cells are moderately differentiated.
G3: The cells are poorly differentiated.
Developed by the American Cancer Society medical and editorial content team with medical review and contribution by the American Society of Clinical Oncology (ASCO).
American Joint Committee on Cancer. Corpus Uteri-Carcinoma and Carcinosarcoma. In: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017:661-669.
Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, et al. FIGO staging of endometrial cancer: 2023. Int J Gynecol Obstet. 2023: 162: 383 - 394.
National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Uterine Neoplasms, Version 2.2024 -- March 6, 2024. Accessed at www.nccn.org/professionals/physician_gls/pdf/uterine.pdf on January 19, 2024.
National Cancer Institute. Endometrial Cancer Prevention (PDQ®)–Health Professional Version, March, 15, 2024. Accessed at www.cancer.gov/types/uterine/hp/endometrial-prevention-pdq#section/all on January 19, 2024.
WHO Classification of Tumours Editorial Board. Female Genital Tumours, 5th ed, IARC, 2020. Vol 4.
Last Revised: February 28, 2025
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.